China Biologic Products (NASDAQ:CBPO) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported $1.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.52, RTT News reports. China Biologic Products had a return on equity of 8.56% and a net margin of 29.46%. The business had revenue of $136.10 million for the quarter. During the same quarter in the previous year, the business earned $0.96 EPS. The company’s revenue for the quarter was up 14.3% on a year-over-year basis.
Shares of CBPO traded up $0.43 during trading hours on Wednesday, hitting $115.73. The company had a trading volume of 100,800 shares, compared to its average volume of 178,334. The firm has a market cap of $4.57 billion, a P/E ratio of 28.79, a P/E/G ratio of 7.05 and a beta of 1.18. The stock’s 50 day moving average price is $115.03 and its 200 day moving average price is $100.82. China Biologic Products has a 52-week low of $69.22 and a 52-week high of $117.68.
A number of research firms have weighed in on CBPO. Zacks Investment Research downgraded China Biologic Products from a “buy” rating to a “hold” rating in a research report on Thursday, October 24th. BidaskClub downgraded China Biologic Products from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. Finally, ValuEngine upgraded China Biologic Products from a “hold” rating to a “buy” rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $92.67.
About China Biologic Products
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
Read More: What is the Bid-Ask Spread?
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.
